PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMesalamine
Mesalamine
Apriso, Canasa, Lialda, Mesalamine, Pentasa, Rowasa, Sfrowasa (mesalamine) is a small molecule pharmaceutical. Mesalamine was first approved as Rowasa on 1987-12-24. It is used to treat proctitis, sigmoid diseases, and ulcerative colitis in the USA.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
digestive system diseasesD004066
Trade Name
FDA
EMA
Apriso, Canasa, Lialda, Mesalamine, Pentasa, Sfrowasa (discontinued: Asacol, Canasa, Delzicol, Mesalamine, Rowasa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mesalamine
Tradename
Company
Number
Date
Products
CANASAAbbVieN-021252 RX2004-11-05
1 products, RLD, RS
ROWASAMylanN-019618 RX1987-12-24
1 products, RLD, RS
SFROWASAMylanN-019618 RX2008-06-20
1 products, RLD
APRISOSalix PharmaceuticalsN-022301 RX2008-10-31
1 products, RLD, RS
LIALDATakedaN-022000 RX2007-01-16
1 products, RLD, RS
PENTASATakedaN-020049 RX1993-05-10
2 products, RLD
Show 5 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aprisoNew Drug Application2024-01-09
asacolNew Drug Application2014-03-07
canasaNew Drug Application2024-09-04
delzicolNew Drug Application2025-01-06
lialdaNew Drug Application2023-10-24
mesalamineANDA2025-01-10
mesalamine rectalANDA2023-12-15
pentasaNew Drug Application2025-01-15
rowasaNew Drug Application2024-07-15
sfrowasaNew Drug Application2024-07-24
Show 1 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ulcerative colitisEFO_0000729D003093K51
proctitisEFO_0005628D011349K62.89
sigmoid diseases—D012810—
Agency Specific
FDA
EMA
Expiration
Code
MESALAMINE, LIALDA, TAKEDA PHARMS USA
2023-06-26NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Mesalamine, Apriso, Valeant Pharms Intl
88656882030-05-01U-1310
Mesalamine, Canasa, Abbvie
82170832028-06-06DP
84360512028-06-06DP
Mesalamine, Rowasa, Mylan Speciality Lp
76458012027-07-24DS, DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07E: Intestinal antiinflammatory agents
— A07EC: Aminosalicylic acid and similar agents
— A07EC02: Mesalazine
HCPCS
No data
Clinical
Clinical Trials
227 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ulcerative colitisD003093EFO_0000729K51——1——1
ColitisD003092EFO_0003872K52.9——1——1
UlcerD014456MPATH_579———1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMesalamine
INNmesalazine
Description
Mesalamine is a monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. It has a role as a non-steroidal anti-inflammatory drug. It is an aromatic amine, an amino acid, a member of phenols, a monocarboxylic acid and a monohydroxybenzoic acid. It is functionally related to a salicylic acid. It is a conjugate acid of a mesalaminate(1-).
Classification
Small molecule
Drug classanti-inflammatory agents (salicylic acid derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1ccc(O)c(C(=O)O)c1
Identifiers
PDB—
CAS-ID89-57-6
RxCUI—
ChEMBL IDCHEMBL704
ChEBI ID6775
PubChem CID4075
DrugBankDB00244
UNII ID4Q81I59GXC (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Canasa – Allergan
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Canasa – Warner Chilcott
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Lialda – Shire
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Pentasa – Shire
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Asacol – Allergan
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Asacol – Warner Chilcott
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Mesalamine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 12,080 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
21,627 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use